@article{Kunzmann2022,
author = {Kevin Kunzmann and Michael J. Grayling and Kim May Lee and David S. Robertson and Kaspar Rufibach and James M. S. Wason},
title = {A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials},
journal = {The American Statistician},
volume = {75},
number = {4},
pages = {424-432},
year  = {2021},
publisher = {Taylor & Francis},
doi = {10.1080/00031305.2021.1901782},
URL = {https://doi.org/10.1080/00031305.2021.1901782},
eprint = {https://doi.org/10.1080/00031305.2021.1901782 }}

@book{Held2020,
   author = {Leonhard Held and Daniel Sabanés Bové},
   city = {Berlin, Heidelberg},
   doi = {10.1007/978-3-662-60792-3},
   isbn = {978-3-662-60791-6},
   publisher = {Springer Berlin Heidelberg},
   title = {Likelihood and Bayesian Inference},
   year = {2020},
}

@book{Spiegelhalter2003,
   author = {David J. Spiegelhalter and Keith R. Abrams and Jonathan P. Myles},
   doi = {10.1002/0470092602},
   isbn = {9780471499756},
   month = {12},
   publisher = {Wiley},
   title = {Bayesian Approaches to Clinical Trials and Health‐Care Evaluation},
   year = {2003},
}

@article{Baumgartner2020,
   author = {Christine Baumgartner and Frederikus A Klok and Marc Carrier and Andreas Limacher and Jeanne Moor and Marc Righini and Jürg-Hans Beer and Martina Peluso and Damiana Rakovic and Menno V Huisman and Drahomir Aujesky},
   doi = {10.1136/bmjopen-2020-040151},
   issn = {2044-6055},
   issue = {11},
   journal = {BMJ Open},
   month = {11},
   pages = {e040151},
   title = {Clinical Surveillance vs. Anticoagulation For low-risk patiEnts with isolated SubSegmental Pulmonary Embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE)},
   volume = {10},
   year = {2020},
}

@article{Rufibach2016,
   author = {Kaspar Rufibach and Hans Ulrich Burger and Markus Abt},
   doi = {10.1002/pst.1764},
   issn = {15391604},
   issue = {5},
   journal = {Pharmaceutical Statistics},
   month = {9},
   pages = {438-446},
   title = {Bayesian predictive power: choice of prior and some recommendations for its use as probability of success in drug development},
   volume = {15},
   year = {2016},
}

@article{OHagan2005,
   author = {Anthony O'Hagan and John W. Stevens and Michael J. Campbell},
   doi = {10.1002/pst.175},
   issn = {1539-1604},
   issue = {3},
   journal = {Pharmaceutical Statistics},
   month = {7},
   pages = {187-201},
   title = {Assurance in clinical trial design},
   volume = {4},
   year = {2005},
}

@book{Grieve2022,
   author = {Andrew P. Grieve},
   city = {Boca Raton},
   doi = {10.1201/9781003218531},
   isbn = {9781003218531},
   month = {4},
   publisher = {Chapman and Hall/CRC},
   title = {Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials},
   year = {2022},
}

